Equity Tips

header ads

CAPITALSTARS PRESENTS EQUITY MARKET UPDATE : 31 JAN 2020

INDIAN FACE  
                      
INDIAN EQUITY BENCHMARK

The benchmark S&P BSE Sensex ended the day near day's low, at 40,723.49 level, down 190.33 points or 0.47 per cent. State Bank of India, IndusInd Bank, and Bharti Airtel were the top gainers at close today, up between 1.6 and 2.3 per cent. Meanwhile, ONGC, PowerGrid, and TCS were the top laggards. In the intra-day trade, Sensex hit a low of 40,701.96 level.
On the NSE, the Nifty50 breached below the crucial 12,000-mark and settled at 11,961.65 level, down 74.15 points or 0.62 per cent. 

GLOBAL FACE


Asian Market-Asian markets close the week with losses amid coronavirus fears. Hong Kong stocks plunged nearly 6% this week as the the spread of the coronavirus took its toll on markets. Elsewhere, South Korea's Kospi (KOSPI) dropped 1.4% on Friday, pushing its weekly loss to 5.7%. Japan's Nikkei 225 (N225) ended Friday 1% higher, but is also down for the week. Elsewhere, South Korea's Kospi (KOSPI) dropped 1.4% on Friday, pushing its weekly loss to 5.7%. Japan's Nikkei 225 (N225) ended Friday 1% higher, but is also down for the week.

U.S. Market-Dow futures drop 200 points as coronavirus keeps investors on edge, taking spotlight off earnings.

European markets-European markets close lower as coronavirus death toll rises European markets decline as coronavirus death toll rises.

NIFTY SPOT



MARKET TALKS

Aurobindo Pharma's JV, Eugia Pharma receives USFDA approval for Methotrexate Tablets
Aurobindo Pharma Limited announced today that its joint venture company, Eugia Pharma Specialities Limited, has received a final approval from the US Food & Drug Administration (USFDA) to manufacture and market Methotrexate tablets, 2.5 mg. Methotrexate tablets are generic version of Dava Pharmaceutical Rheumatrex Tablets. The product will be launched in March 2020. The approved product has an estimated market size of US$ 98 million for the twelve months ending December 2019, according to IQVIA. 

Indiabulls Real Estate board approves merger of some residential and commercial projects of Embassy Properties
Indiabulls Real Estate (IBREL) Board has discussed & considered the proposal of the reorganisation of Company's business and in-principally approved the proposal of merger of certain ongoing, completed & planned residential & commercial projects of Embassy Property Developments P Ltd (Embassy) with IBREL. Embassy is in discussions with financial investors such as Blackstone and others to raise up to $200 million before the Merger.

Alembic Pharma's Q3 net profit drops 76% yoy to Rs92 lakh 
Alembic Pharma's total income for Q3FY20 fell 42% yoy to Rs14.83cr, mainly due to a fall in revenues from the API business. The real estate business also suffered a huge decline.Its net profit stood at Rs92 lakh in the quarter vs. Rs3.9cr yoy; a plunge of 76% yoy.Profit before tax stood at Rs94 lakh. Basic EPS came in at Rs2.65/share vs. Rs2.05/share yoy.

SBI records its highest ever quarterly net profit at Rs5,583cr in Q3  
State Bank of India registered a net profit of Rs5,583cr during Q3FY20, a yoy increase of 41.18%  This is also the highest ever quarterly net profit recorded by the Bank.  The bank's net NPA came in at 2.65% vs. 2.79% and gross NPA stood at 6.94% vs. 7.19% qoq.  During the quarter, the bank exercised the option of lower tax rate taking a one-time hit of Rs1,333cr. Excluding the impact of this one-time additional hit, net profit in Q3FY20 would have been Rs6,916cr vs. Rs3,955cr in Q3FY19.

NAME OF THE STOCK : DMART

DATE :  30/1/2020

SEGMENT : CASH

CHART TYPE : Candlestick

EXCHANGE : NSE

VOLUME.MACD, RSI. : TECHNICAL INDICATORS USED


INVESTMENT ADVICE: CS CALL - BUY DMART IN CASH NR CMP 2050 TGT 2100 SL 2000

RATIONALE FOR ARRIVING INVESTMENT ADVICE: We Provide Trading calls on the basis of the following key points: 
1. Technical Analysis (Use of Candlestick Charts, Technical Indicators like RSI, MACD, Stochastic, ADX etc,) 
2. Fundamentals of the Company 
3. Live Market News & Updates (Company related, Sector related, Economy related, political, Global news, etc.) 
4. Tracking of Market Data’s (GDP, IIP, CPI, WPI, TRADE BALANCE, etc.) 
5. Tracking of Market Events like (RBI POLICY, FED POLICY, ECB MEETING, and OPEC MEETING, etc.) 
6. Tracking of Market Trends like Bullish Trend, Bearish Trend, and Consolidation, etc.


DISCLAIMER

The information and views in this report & all the service we provide are believed to be reliable, but we do not accept any responsibility for errors of fact or opinion. Investors have the right to choose the product/s that suits them the most. Sincere efforts have been made to present the right investment perspective. The information contained herein is based on analysis and upon sources that we consider reliable. This material is for personal information and based upon it & takes no responsibility. The information given herein should be treated as the only factor while making investment decisions. The report does not provide individually tailor-made investment advice. My research recommends that investors independently evaluate particular investments and strategies, and encourages investors to seek the advice of a financial adviser. CapitalStars shall not be responsible for any transaction conducted based on the information given in this report, which is in violation of rules and regulations of regulators. The price projections shown are not necessarily indicative of future price performance. The information herein, together with all estimates and forecasts, can change without notice. It is understood that anyone who is browsing through the site has done so at his free will and does not read any views expressed as a recommendation for which either the site or its owners or anyone can be held responsible for. Investment & Trading in Securities Markets is always subjected to market risk.

CLICK HERE FOR GETTING DETAILS & JOIN OUR BEST ADVISORY  -

Visit our Link : https://www.capitalstars.com/free-trial

Visit My Website: https://www.capitalstars.com/

CAPITALSTARS CALL US : 9977499927

Derivatives Tips , Intraday Stock Tips , FreeTrading Tips, Sebi Registered advisory






Post a Comment

0 Comments